Vyriad

Vyriad

Biotechnology

Rochester, MN 2,957 followers

Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deliver genes directly to cells.

About us

At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs. Phase 1-2 Clinical Studies are currently active in: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Breast cancer Bladder cancer Other cancer types Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical institutions.

Industry
Biotechnology
Company size
51-200 employees
Headquarters
Rochester, MN
Type
Privately Held
Founded
2015

Locations

Employees at Vyriad

Updates

Similar pages

Browse jobs

Funding

Vyriad 4 total rounds

Last Round

Series B

US$ 29.5M

See more info on crunchbase